Shrinkage
The Hepatitis Drug Market Is Worse Than Wall Street Realizes
Analysts haven't gotten the message, but some drugmakers have.
This article is for subscribers only.
And then there were three.
Johnson & Johnson and Merck & Co. Inc. have both recently halted development of drugs to treat hepatitis C (HCV), with no plans to work on any others. This capitulation leaves the market largely split between Gilead Sciences Inc., AbbVie Inc., and a drug Merck already has on the market.